Main navigation

Unleash growth by optimising recombinant protein manufacture

Our QTL technology creates and customises premium recombinant proteins that are patent protected and designed to dominate your chosen market.

Solving big problems with support from the Bill & Melinda Gates Foundation

Our technology and expertise in genomics and strain breeding is making vaccines available to low and middle income countries using recombinant albumin. That’s just the start.

Therapeutics

Biosimilars

  • Consistent high quality bioequivalence
  • Higher titre and net yield
  • Reduced manufacturing plant
  • Overcoming manufacturing secrets
  • Potential earlier market entry
FIND OUT MORE

Supply chain proteins

  • Meet supply deficits
  • Significantly lower costs
  • Substantial scaling
  • Technically challenging proteins
  • Circumvent manufacturing secrets
FIND OUT MORE

Discovery biologics

  • Commercially scalable
  • Timely batches for testing
  • Fast and dependable
  • Regulatory friendly
  • Attractive to licensors
FIND OUT MORE

We can help you grow

Partner with us to optimise existing recombinant proteins, license new ones, and transform your supply chain.

Ways to engage

Solve a technical problem

  • Technically complex proteins
  • New indications of established proteins
  • Reducing costs of manufacture
TROUBLESHOOTING

Partner with us

  • Bespoke premium biosimilars
  • Price competitive markets
  • Technically challenging biosimilars
PARTNERSHIPS

License biosimilars

  • Insulin glargine
  • Semaglutide precursor
  • Recombinant albumin
LICENSING